Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02558296 · ClinicalTrials.gov registry record · Phase 3
Bexagliflozin Efficacy and Safety Trial
A Phase 3 study, sponsored by Theracos.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,700
- Enrollment target
NCT02558296 is a Phase 3 study that has completed, run by Theracos. The registered enrollment target is 1,700 participants.
The verdict
NCT02558296, a Phase 3 study, has completed, sponsored by Theracos.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,700 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the effect of bexagliflozin in lowering hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM) and increased risk of cardiovascular adverse events. The data from this study will be combined with the data from other bexagliflozin studies in a meta-analysis of CV safety outcomes.
Interventions
- DRUG Placebo
- DRUG Bexagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,700 participants |
| Start Date | 2015-10 |
| Est. Completion | 2019-10-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02558296
The ClinicalTrials.gov registry entry for NCT02558296 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,700 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theracos, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02558296 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02558296 about?
NCT02558296 is a clinical study titled "Bexagliflozin Efficacy and Safety Trial". The purpose of this study is to investigate the effect of bexagliflozin in lowering hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM) and increased risk of cardiovascular adverse events. The data from this study will be combined with the data from other bexagliflozin st...
What is the current status of trial NCT02558296?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,700 participants. The study started on 2015-10. Estimated completion is 2019-10-23.
What interventions are being tested in trial NCT02558296?
The interventions under investigation include: Placebo (DRUG), Bexagliflozin (DRUG).
Who is sponsoring clinical trial NCT02558296?
This trial is sponsored by Theracos, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.